LENZ THERAPEUTICS, INC. Shareholders' Equity
LENZ THERAPEUTICS, INC. (LENZ) had Shareholders' Equity of $219.26 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $219.26M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $246.49M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $284.34M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $193.93M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $219.26M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $246.49M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $284.34M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $193.93M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $206.37M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | $192.01M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $204.08M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | $215.28M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $192.92M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $198.17M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | -$92.71M 10-K · filed 2026-03-24 | $183.58M 10-K · filed 2024-02-27 |
| 2023-09-30 | -$69.57M 10-Q · filed 2024-11-06 | $204.02M 10-Q · filed 2023-11-13 |
| 2023-06-30 | -$51.21M 10-Q · filed 2024-11-06 | $224.15M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$36.68M 10-Q · filed 2024-11-06 | $276.22M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$24.17M 10-K · filed 2025-03-19 | $296.29M 10-K · filed 2023-03-20 |
| 2022-09-30 | $316.45M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $338.46M 10-Q · filed 2023-11-13 | |
| 2022-03-31 | $361.30M 10-Q · filed 2023-11-13 | |
| 2021-12-31 | $384.05M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $400.13M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $379.18M 10-Q · filed 2022-11-09 | |
| 2021-03-31 | -$84.08M 10-Q · filed 2022-11-09 | |
| 2020-12-31 | -$65.41M 10-K · filed 2023-03-20 | |
| 2020-09-30 | -$4.79M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$1.45M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | -$2.36M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | -$2.22M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |